Delivery Order SPE2DB24D2217-SPE2DB25FJXPS
- Not listed
- The Defense Logistics Agency awarded a $1,687.48 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for ProQuad vials with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationships with DLA for pharmaceutical supply to...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,543.30 to AmerisourceBergen Drug Corp for ProQuad vials on September 12, 2025, with an ultimate completion date of October 3, 2025. This firm fixed-price delivery order, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of ProQuad vials valued at $13,234.64 with a completion date of August 11, 2025. This non-competitive delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The performance location is...
- The Defense Logistics Agency (DLA) awarded a $6,469.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $3,374.88 to AmerisourceBergen Drug Corp for ProQuad vials on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery order will be fulfilled at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,670.90 to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.9 million through December 2026. ProQuad is a combination vaccine used to protect...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of ProQuad vials, a combination vaccine product. This firm fixed-price delivery order, valued at $1,687.48, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical support vehicle running through December 2026. The order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of September 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA for pharmaceutical and...
- The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- SPE2DB24D2217Indefinite Delivery Contract
- SPE2DB24D2217-SPE2DB25FJXPSDelivery Order
The Defense Logistics Agency (DLA) awarded a $1,687.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 19, 2025, with a completion date of September 10, 2025. This non-set-aside competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. ProQuad vials are a combination vaccine product, and this delivery order demonstrates AmerisourceBergen's ongoing role as a critical pharmaceutical distributor for federal military healthcare systems. As a major pharmaceutical and healthcare solutions provider, AmerisourceBergen supplies an extensive portfolio of medical products to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities through its prime vendor agreements. The company's consistent receipt of competitively awarded delivery orders across varying dollar amounts reflects its capability to fulfill federal medical procurement requirements efficiently and reliably within the DLA's global pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/19/25 |